Lipocine Reports Q1 2023 Financial Results and Updates on Clinical Programs.
Lipocine reported a pure play biotech for potency enhancements and blocked periods. The company provided preliminary updates for its LPCI-977 and LPCX-100 clinical trials despite a significant operating cash run-rate.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed